Content area
GW Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
GW Pharmaceuticals Plc (GW Pharmaceuticals), a subsidiary of Jazz Pharmaceuticals, is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, England, the UK
GW Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.